Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Announces Reverse Stock Split

NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it will effect a 1-for-12 reverse stock split in order to help regain compliance with the Nasdaq Capital Market's listing requirements.

In October, the company disclosed that it had been notified that it failed to meet the Nasdaq's $1 minimum bid price requirement for continued listing on the exchange. Following the reverse stock split — which is set to take effect at the start of trading tomorrow — every 12 ordinary shares of Rosetta will be consolidated into one share. Immediately after the reverse stock split, Rosetta will have approximately 1.9 million shares issued and outstanding.

During midday trading, Rosetta's stock was down nearly 4 percent to $.43.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.